Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 4/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 1/20 | 0.35 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27773780 | 1.00 | KDM4E (0.36) | KDM4EHPGDALDH1A1HTTBACE1 | |
| SCHEMBL31003034 | 0.82 | PSMB5 (0.48) | ALDH1A1BACE1PSMB5MMP8REN | |
| SCHEMBL939400 | 0.74 | LMNA (0.45) | HPGDALDH1A1PSMB5MMP8REN | |
| SCHEMBL16569135 | 0.74 | LMNA (0.45) | HPGDALDH1A1PSMB5MMP8REN | |
| SCHEMBL5494415 | 0.71 | HPGD (0.38) | HPGDBACE1PSMB5RENANPEP | |
| SCHEMBL31692789 | 0.71 | CACNA2D1 (0.40) | — | |
| SCHEMBL29885722 | 0.70 | CACNA2D1 (0.42) | ALDH1A1 | |
| SCHEMBL31633387 | 0.70 | METAP2 (0.41) | HTTPSMB5RENANPEPLAP3 | |
| SCHEMBL5843971 | 0.70 | ALDH1A1 (0.42) | KDM4EHPGDALDH1A1MMP8RCE1 | |
| SCHEMBL9193585 | 0.70 | LMNA (0.38) | KDM4EALDH1A1BACE1RENANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106635994-A | Culture medium additive for preparing autophagosomes-type tumor vaccine and preparing method thereof | 东南大学 | 2017-05-10 | — | — | CN | claimed |
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-20210361683-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE CONTRACTURES | CHILDRENS HOSPITAL MED CT (US) | 2021-11-25 | — | — | US | disclosed |
| EP-3801581-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE CONTRACTURES | Children's Hospital Medical Center (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9878999-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9233115-B2 | Proteasome inhibitors and methods of using the same | MILLENNIUM PHARMACEUTICALS INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | CEPHALON, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140073650-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-7223745-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006086600-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1658255-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| US-20050059636-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005016859-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | PSMB3, PSME3, PSMD3 | KDM4E 2332/4885HPGD 3647/4885ALDH1A1 4471/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | KDM4E 1703/4885HPGD 3107/4885ALDH1A1 3935/4885 |
| US-20140073650-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | PSMB3, PSME3, PSMD3 | KDM4E 2332/4885HPGD 3647/4885ALDH1A1 4471/4885 |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | PSMB3, PSME3, PSMD3 | KDM4E 2332/4885HPGD 3647/4885ALDH1A1 4471/4885 |
| US-20140088042-A1 | Proteasome Inhibitors And Methods Of Using The Same | PSMB11, PSMB5, PSMB6 | KDM4E 1703/4885HPGD 3107/4885ALDH1A1 3935/4885 |
| US-20060189806-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | KDM4E 1640/4885HPGD 3103/4885ALDH1A1 3902/4885 |
| US-20050059636-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | KDM4E 1703/4885HPGD 3107/4885ALDH1A1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.